Clinical trials: Cardiovascular Outcomes
Paroxysmal AF, Atrial Arrhythmia
BaLloon-based PFA Ablation poST Approval Outcomes for PAF and PersAF
This study is designed to obtain real-world clinical evidence on the safety and effectiveness of the Volt PFA System in various use cases, with a sub study designed to address additional clinical evidence needs in…
- Conditions
- Paroxysmal AF, Atrial Arrhythmia, Atrial Fibrillation, Persistent Atrial Fibrillation
- Trial name
- BLAST-OFF (NCT07181590)
- Testing
- Pulsed Field Ablation
- Where
- 22 sites in Austria, Belgium and 10 more
- Volunteers
- 300 people
- Sponsor
- Abbott Medical Devices
Prevention & Control
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
The primary objectives of this study are: To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction…
- Trial name
- COMPASS (NCT01776424)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Pantoprazole
- Where
- 565 sites in United States, Argentina and 31 more
- Volunteers
- 27,395 people
- Sponsor
- Bayer
Pulmonary Embolism
Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System
The objective of this study is to evaluate real world long-term functional outcomes, safety and performance of the Indigo Aspiration System for the treatment of pulmonary embolism (PE).
- Trial name
- NCT04798261
- Testing
- Indigo Aspiration System
- Where
- 79 sites in United States, Australia and 10 more
- Volunteers
- 1,500 people
- Sponsor
- Penumbra Inc.
Cerebrovascular Accident, Transient Ischemic Attack
Safety Study of Atomoxetine and Cerebrovascular Outcomes
Using a proprietary insurance health claims database, Eli Lilly and Company has contracted with an external party to conduct a retrospective cohort study of health claims for the time period from 1 January 2003 through 31…
- Conditions
- Cerebrovascular Accident, Transient Ischemic Attack, ADHD
- Trial name
- NCT00634439
- Testing
- atomoxetine, Stimulants, No intervention (general population)
- Where
- United States
- Volunteers
- 72,000 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World
This is a retrospective database study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for patients in the US, to evaluate the effectiveness of once-weekly semaglutide…
- Conditions
- Overweight, Obesity, Atherosclerotic Cardiovascular Disease (ASCVD)
- Trial name
- SCORE (NCT06874751)
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 45,456 people
- Sponsor
- Novo Nordisk A/S
Heart Failure
Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)
Evaluation of the risk factors associated with Heart Failure (HF) worsening (measured by hospitalizations and emergency visits because of HF exacerbations) in Spanish patients with Atrial Fibrilation and HF treated with…
- Trial name
- FARAONIC (NCT03455439)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Spain
- Volunteers
- 552 people
- Sponsor
- Bayer
Multiple Myeloma, Relapsed Hematologic Malignancy
PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
This study will evaluate the feasibility of a digital health coaching program for adults with relapsed or refractory multiple myeloma (R/R MM). One hundred adults with R/R MM will be enrolled at The University of Washington.
- Trial name
- NCT05956457
- Testing
- Digital Health Coaching Program, Fitbit
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Pack Health
Acute Coronary Syndrome
The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or urgent coronary revascularization (e.g.
- Trial name
- SOLID-TIMI 52 (NCT01000727)
- Testing
- Darapladib 160 mg, Standard Therapy
- Where
- 914 sites in United States, Argentina and 34 more
- Volunteers
- 13,026 people
- Sponsor
- GlaxoSmithKline
Aortic Valve Stenosis
RESPOND EDGE Post Market Study
The purpose of the RESPOND EDGE post market study is to collect real world clinical and device performance outcomes data with the Lotus Edge™ Valve System used in routine clinical practice to demonstrate that the commercially…
- Trial name
- RESPOND EDGE (NCT04009720)
- Testing
- Lotus Edge Device
- Where
- 13 sites in Denmark, Finland and 7 more
- Volunteers
- 200 people
- Sponsor
- Boston Scientific Corporation
Prevention of Thromboembolic Events, Atrial Fibrillation
An Observational Study (Called RETAF-PS) Using a Patient Survey to Learn More About Treatment Outcomes in Patients With Irregular and Often Rapid Heartbeat (Atrial Fibrillation) Treated With Apixaban in a Real World Setting
This is an observational study in which data from people with atrial fibrillation who received or are currently receiving the drug apixaban to prevent thromboembolic events (blood clots that travel through the blood stream to…
- Trial name
- NCT05471830
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Bayer
Cardiac Surgical Procedures, Coronary Artery Disease
Clinical Outcomes in Patients Treated With SternaLock Blu
The primary objective of this study is to evaluate the rate of deep sternal wound infection at 30 days post-operative following a full median sternotomy in patients treated with SternaLock Blu for rigid sternal fixation.
- Conditions
- Cardiac Surgical Procedures, Coronary Artery Disease, Heart Valve Diseases
- Trial name
- SECURE (NCT03709693)
- Testing
- SternaLock Blu
- Where
- 4 sites in United States
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Zimmer Biomet
Heart Disease, Heart Failure
Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany
Heart failure (HF) is a global public health issue that affects more than 63 million people worldwide. The clinical and economic burden of HF on health care systems is substantial.
- Conditions
- Heart Disease, Heart Failure, Cardiovascular Disease, Heart Failure, Systolic
- Trial name
- PHRASE-HF (NCT06675552)
- Where
- 6 sites in Germany
- Volunteers
- 338 people
- Sponsor
- AstraZeneca
Alpha-Thalassemia, Beta-Thalassemia
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases.
- Conditions
- Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT06539169
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- xCures
Peripheral Arterial Disease
DANCE Partner: Inflammatory Biomarker Analysis by Femoropopliteal Revascularization Method and Treatment Outcomes
This is a prospective, multi-center, observational registry to document the baseline, 24-hour and 30-day inflammatory response and procedural outcomes out to 12 month follow-up after femoropopliteal angioplasty or…
- Trial name
- NCT02469532
- Testing
- Balloon Angioplasty, Atherectomy System
- Where
- 6 sites in United States
- Volunteers
- 31 people
- Sponsor
- Mercator MedSystems, Inc.
Coronary Artery Disease
The Use of Aging Biomarkers to Predict Adverse Outcomes After Cardiac Surgery
Cardiac surgery associated acute kidney injury (CSA-AKI) has been recognized as the second most common cause of hospital acquired AKI.
- Trial name
- NCT02496234
- Where
- United States
- Volunteers
- 186 people
- Sponsor
- Sapere Bio
Heart Failure, Congestive
HEAL-HF: A Cardiac Resynchronization Therapy (CRT) Outcomes Study
The literature shows that approximately 40% of individuals who receive a cardiac resynchronization therapy (CRT) device for symptomatic congestive heart failure (CHF) do not have a clinical benefit from the device.
- Trial name
- NCT00370526
- Testing
- Acute hemodynamic assessment using PV Loops (CD Leycom, The Netherlands) during LV lead placement
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 100 people
- Sponsor
- Stereotaxis
Plaque, Atherosclerotic Disease
BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population
The BioImage Study is a study of the characteristics of subclinical cardiovascular disease, as measured by imaging modalities, unsupervised circulating biomarker measurements, and risk factors that predict progression to overt…
- Conditions
- Plaque, Atherosclerotic Disease, Heart Disease, Stroke
- Trial name
- NCT00738725
- Where
- 2 sites in United States
- Volunteers
- 7,687 people, healthy volunteers welcome
- Sponsor
- BG Medicine, Inc
Diabetes Mellitus, Type 2
A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes
The primary research question is to evaluate whether, among patients with type 2 diabetes mellitus (T2D), initiation of empagliflozin changes the adjusted incidence of outcomes compared with initiation of Glucagon-Like Peptide-1…
- Trial name
- NCT03993132
- Testing
- Empagliflozin, Liraglutide
- Where
- Denmark
- Volunteers
- 26,774 people
- Sponsor
- Boehringer Ingelheim
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Warfarin for the first time…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947998
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Warfarin, Antiplatelet drugs
- Where
- United Kingdom
- Volunteers
- 50,299 people
- Sponsor
- Bayer
Hypertension
Precision Nudging for Hypertension Management: Observational Study
The purpose of the proposed observational study is to explore the relations between data-driven personalization and equitable health outcomes in a digital health intervention (DHI) for hypertension management.
- Trial name
- NCT06354192
- Testing
- Precision Nudging for Hypertension Management
- Where
- United States
- Volunteers
- 12,000 people
- Sponsor
- Lirio